Considering Psychedelics as a Viable Therapeutic

July 12, 2022 3:15pm

Todd A. Harrison
Venable LLP

Michael Labson
Covington & Burling LLP

Seth A. Mailhot
Husch Blackwell LLP

Kimberly Chew
Senior Counsel, Co-leader of Psychedelics and Emerging Therapies Practice Group
Husch Blackwell LLP

Jackie von Salm, PhD
Co-Founder & Chief Scientific Officer

Recent studies are pointing to the promise for psychedelic drugs like LSD and psilocybin to help alleviate depression, anxiety and addiction. This panel will explore the legal status of psychedelic drugs under federal law, as we explore the DEA’s 2022 production goals for psychedelics, and the status of psychedelics as a Schedule I controlled substance. Topics include:

  • Reviewing the legal status of Psilocybin, MDMA, ibogaine and DMT
  • Understanding the basics of psychedelic therapy and navigating risks
  • Exploring Psilocybin designation as a breakthrough therapy